Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: May 21, 2026
Trifunctional TNG Gel

Tri-Active Contraceptive Gel

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Beijing Institute of Geriatrics, North Carolina State University
Active
Last updated: May 18, 2026
Carica Papaya Extract
  • User: Female/Male
  • Hormonal: Not Yet Determined
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Rajasthan, India, Punjab Agricultural University and Thapar Institute
Active
Last updated: May 18, 2026
HER-102

Lactobacilli, LJ-102

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Hervana Bio
Active
Last updated: May 18, 2026
Lonidamine Derivatives

Gamendazole, H2-Gamendazole, Adjudin, BHD

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Kansas Medical Center, University of Minnesota, Nantong University
Active
Last updated: May 18, 2026
Methanolic Dry Root Extract of P. Hydropiper
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Darrang College
Active
Last updated: May 18, 2026
Triptonide
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): UCLA, Reno School of Medicine, Family Planning Research Institute of Guangdong Province, Male Contraceptive Initiative
Active
Last updated: May 9, 2026
Woman's Condom
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Barrier
  • Intended Duration: Pericoital
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): PATH, NICHD, SIPPR (SIBPT), University of Witwatersrand
Active
Last updated: May 9, 2026
Dimethandrolone Undecanoate (DMAU)
  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Phase II
  • Developer(s)/Researcher(s): BIOQUAL, Inc, NICHD, Washington State University, Lundquist Institute at Harbor UCLA Medical Center, University of Washington
Active
Last updated: May 9, 2026
Weekly Mifepristone
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase III
  • Developer(s)/Researcher(s): Women on Waves, Karolinska Institute, Leiden University Medical Center